|
Dr. Grillo-Lopez was Chief Medical Officer and Senior Vice President, Medical and Regulatory Affairs at IDEC Pharmaceuticals from 1992 until his retirement in 2001. At IDEC he led clinical development of IDEC-C2B8 (Rituxan®, MabThera) which was approved in 1997 by the FDA for the treatment of patients with low-grade or follicular non-Hodgkin's lymphoma. At IDEC he also supervised the development of Zevalin which is the first radioimmunotherapy approved for the treatment of cancer. For his medical work he was awarded the Leukemia Society of America Triumph Award, the Cure for Lymphoma Foundation Trailblazer Award and the Peter McCuen Cancer Research Excellence Award from the University of California. Prior to his groundbreaking work at IDEC, he was Executive Medical Director for International Clinical Research Development at DuPont Merck for five years, Vice President, clinical Therapeutics and Director, Clinical Oncology Research at Parke Davis (Warner Lambert) for seven years and was Associate Professor of Medicine in the Department of Hematology and Oncology at the University of Michigan. Dr. Grillo-Lopez trained as a hematologist and oncologist at the University of Puerto Rico School of Medicine, San Juan, where he received his medical degree and later founded the Puerto Rico Society of Hematology and the Latin American Society of Hematology. Dr. Grillo-Lopez has authored over 200 publications, primarily in the fields of hematology and oncology, including co-authorship of the current international response criteria for lymphoma. | 